The Actavis Group has received approval to market generic ranitidine oral solution USP in the 15-mg/mL strength. This product is the generic equivalent of GlaxoSmithKline’s Zantac drug Syrup. Ranitidine is indicated for the treatment and prevention of ulcers and gastroesoph-ageal reflux disease (GERD) and for the treatment of conditions caused by high acid secretion.